Texture analysis of 3D models for the prediction of the grade of clear cell renal cell carcinoma of the kidney (pilot study)

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Aim. To evaluate the possibilities of textural analysis of 3D models in differentiating the degree of nuclear dysplasia of the clear cell renal cell carcinoma (ccRCC).

Materials and methods. The specimens after surgical treatment of 190 patients with ccRCC were analyzed. In all cases, nephron-sparing surgery (NSS) was performed through laparoscopic access. The clinical characteristics were evaluated, including age, gender, tumor localization (side, surface and segments), absolute tumor volume, Charlson comorbidity index, body mass index, nephrometry scores (RENAL, PADOVA, C-index). Patients were divided into 2 groups. In group 1, there were 119 patients with the ccRCC of Grade 1 or 2, while group 2 consisted of 71 patients with ccRCC of Grade 3 and 4. All patients underwent 3D virtual planning of procedure using the 3D modeling program «Amira». At the first stage, two experienced radiologists performed manual segmentation of 3D models of kidney parenchyma tumors. At the second stage, the tumor shape was analyzed with a mathematical calculation of three indicators and more than 300 textural features of statistics of types 1-2 were extracted. Further, an intellectual analysis was carried out. For the evaluation of tumor grade according to Furman system, the classification problem was solved using the machine learning algorithm Stochastic Gradient Descent and cross-validation k=5.

Results. The accuracy of classification for the two groups of Grade 1 or 2 and Grade 3 or 4 on the F1 metric was 72.2. To build the model, the following parameters were selected: the absolute tumor volume, the Charlson comorbidity index, "Energy", the first quartile and the second decile of the pixel intensity distribution.

Conclusion. The texture analysis of 3D models for the prediction of Fuhrman grade in ccRCC demonstrated satisfactory quality for two groups of Grade 1 or 2 and Grade 3 or 4 nuclear dysplasia.

Full Text

Restricted Access

About the authors

A. V. Konyshev

Institute of Urology and Reproductive Health, FGAOU VO I.M. Sechenov First Moscow State Medical University

Author for correspondence.
Email: urokulez@yandex.ru

urologist, applicant of the Institute of Urology and Reproductive Health, FGAOU VO I.M. Sechenov First Moscow State Medical University

Russian Federation, Moscow

P. V. Glybochko

Institute of Urology and Reproductive Health, FGAOU VO I.M. Sechenov First Moscow State Medical University

Email: glybochko_p_v@staff.sechenov.ru

academician of RSA, professor, Ph.D., MD, rector, FGAOU VO I.M. Sechenov First Moscow State Medical University

Russian Federation, Moscow

D. V. Butnaru

Institute of Urology and Reproductive Health, FGAOU VO I.M. Sechenov First Moscow State Medical University

Email: butnaru_d_v@staff.sechenov.ru

Ph.D., urologist, associate professor, Deputy Director on the Scientific work of Institute of Urology and Reproductive Health, FGAOU VO I.M. Sechenov First Moscow State Medical University (Sechenov University)

Russian Federation, Moscow

Yu. G. Alyaev

Institute of Urology and Reproductive Health, FGAOU VO I.M. Sechenov First Moscow State Medical University

Email: ugalyaev@mail.ru

corresponding member of RAS, Ph.D., MD, professor at the Institute of Urology and Reproductive Health, FGAOU VO I.M. Sechenov First Moscow State Medical University

Russian Federation, Moscow

E. S. Syrota

Institute of Urology and Reproductive Health, FGAOU VO I.M. Sechenov First Moscow State Medical University; FGBU Center for Information Technologies in Design of the Russian Academy of Sciences (CITP)

Email: sirota_e_s@staff.sechenov.ru

Ph.D., MD, urologist, oncologist, Chief of the Center of Neural Network Technologies of Institute of Urology and Reproductive Health, FGAOU VO I.M. Sechenov First Moscow State Medical University

Russian Federation, Moscow; Odintsovo, Moscow Region

M. M. Chernenky

Institute of Urology and Reproductive Health, FGAOU VO I.M. Sechenov First Moscow State Medical University

Email: chernenkiy_m_m@staff.sechenov.ru

physical engineer at the Institute of Urology and Reproductive Health, FGAOU VO I.M. Sechenov First Moscow State Medical University

Russian Federation, Moscow

I. M. Chernenky

Institute of Urology and Reproductive Health, FGAOU VO I.M. Sechenov First Moscow State Medical University

Email: chernenkiy_i_m@staff.sechenov.ru

инженер-программист Institute of Urology and Reproductive Health, FGAOU VO I.M. Sechenov First Moscow State Medical University

Russian Federation, Moscow

D. N. Fiev

Institute of Urology and Reproductive Health, FGAOU VO I.M. Sechenov First Moscow State Medical University

Email: fiev_d_n@staff.sechenov.ru

Ph.D., MD, urologist, chief researcher of the Institute of Urology and Reproductive Health, FGAOU VO I.M. Sechenov First Moscow State Medical University

Russian Federation, Moscow

A. V. Proskura

Institute of Urology and Reproductive Health, FGAOU VO I.M. Sechenov First Moscow State Medical University

Email: proskura_a_v_1@staff.sechenov.ru

Ph.D., urologist, oncologist, assistant of the Institute for Urology and Human Reproductive Health of I.M. Sechenov First Moscow State Medical University

Russian Federation, Moscow

A. R. Adzhiev

Institute of Urology and Reproductive Health, FGAOU VO I.M. Sechenov First Moscow State Medical University

Email: adzhiev-1998@bk.ru

2-year resident, Institute of Urology and Reproductive Health, FGAOU VO I.M. Sechenov First Moscow State Medical University

Russian Federation, Moscow

S. A. Amrakhov

Institute of Urology and Reproductive Health, FGAOU VO I.M. Sechenov First Moscow State Medical University

Email: gradmonaco@yandex.ru

urologist, Ph.D. student at the Institute of Urology and Reproductive Health, FGAOU VO I.M. Sechenov First Moscow State Medical University

Russian Federation, Moscow

A. A. Izmailova

Institute of Urology and Reproductive Health, FGAOU VO I.M. Sechenov First Moscow State Medical University

Email: izmailovaa20@gmail.com

4-year student, FGAOU VO I.M. Sechenov First Moscow State Medical University

Russian Federation, Moscow

I. P. Sarkisyan

Email: ig.sark.0201@gmail.com

4-year student, FGAOU VO I.M. Sechenov First Moscow State Medical University

Russian Federation

M. Y. Alekseeva

Email: alexeeva.marina-dc@yandex.ru

6-year student, FGAOU VO I.M. Sechenov First Moscow State Medical University

Russian Federation

V. N. Gridin

FGBU Center for Information Technologies in Design of the Russian Academy of Sciences (CITP)

Email: info@ditc.ras.ru

Ph.D. in technical sciences, professor, scientific chief of FGBU Center for Information Technologies in Design of the Russian Academy of Sciences (CITP)

Russian Federation, Odintsovo, Moscow Region

P. V. Bochkarev

FGBU Center for Information Technologies in Design of the Russian Academy of Sciences (CITP)

Email: info@ditc.ras.ru

junior researcher at the FGBU Center for Information Technologies in Design of the Russian Academy of Sciences (CITP)

Russian Federation, Odintsovo, Moscow Region

I. A. Kuznetsov

FGBU Center for Information Technologies in Design of the Russian Academy of Sciences (CITP)

Email: info@ditc.ras.ru

Ph.D. in technical sciences, associate professor, Head of the Laboratory of FGBU Center for Information Technologies in Design of the Russian Academy of Sciences (CITP)

Russian Federation, Odintsovo, Moscow Region

References

  1. Bhupender S. Chhikara, Keykavous Parang. Global Cancer Statistics 2022: The Trends Projection Analysis Chem. Biol. Lett. 2023;10(1):451.
  2. Sung H., Ferlay J., Siegel R. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021;71(3):209–249.
  3. Merabishvili V.M., Poltoratsky A.N., Nosov A.K., etc. The state of cancer care in Russia. Kidney cancer (morbidity, mortality, reliability of accounting, one-year and one-year mortality, histological structure). Part 1. Oncourology 2021;17(2):182–194. Russian (Мерабишвили В.М., Полторацкий А.Н., Носов А.К. и др. Состояние онкологической помощи в России. Рак почки (заболеваемость, смертность, достоверность учета, одногодичная и погодичная летальность, гистологическая структура). Часть 1. Онкоурология 2021;17(2):182–194).
  4. Fuhrman S.A., Lasky L.C., Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982;6(7):655–663.
  5. Erdoğan F., Demirel A., Polat Ö. Prognostic significance of morphologic parameters in renal cell carcinoma. Int J Clin Pract. 2004;58(4):333–336
  6. Ljungberg B, Cowan NC, Hanbury DC, Hora M, Kuczyk MA, Merseburger AS, et al. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol. 2010;58:398–406.
  7. Pantuck AJ, Zeng G, Belldegrun AS, Figlin RA. Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway. Clin Cancer Res 2003;9:4641–4652.
  8. Davaro F., Roberts J. et al Robotic surgery does not afect upstaging of T1 renal masses Journal of Robotic Surgery, 2019.
  9. Alyaev Yu.G., Glybochko P.V., Pushkar D.Yu. Russian clinical guidelines for urology. 2016. M., GEOTAR-Media. 496 p. Russian (Аляев Ю.Г., Глыбочко П.В., Пушкарь Д.Ю. Российские клинические рекомендации по урологии. 2016. М., ГЭОТАР-Медиа. 496 с.).
  10. Patel H.D. Semerjian A. et al. Surgical removal of renal tumors with low metastatic potential based on clinical radiographic size: A systematic review of the literature. Urologic Oncology: Seminars and Original Investigations. 2019;37:519−524.
  11. Fujii Y., Komai Y., Saito K. et al. Incidence of benign pathologic lesions at partial nephrectomy for presumed RCC renal masses: Japanese dual-center experience with 176 consecutive patients. Urology. 2008; 72:598–602.
  12. Frank I., Blute M.L., Cheville J.C., et al: Solid renal tumors: an analysis of pathological features related to tumor size. J Urol. 2003;170:2217–2220.
  13. Kim J.H., Li S., Khandwala Y., Chung K.J., Park H.K., Chung B.I. Association of prevalence of benign pathologic fifindings after partial nephrectomy with preoperative imaging patterns in the United States from 2007 to 2014. JAMA Surg. 2019;154:225–231.
  14. Snyder M.E., Bach A., Kattan M.W., Raj G.V., Reuter V.E., Russo P. Incidence of benign lesions for clinically localized renal masses smaller than 7 cm in radiological diameter: influence of sex. J Urol. 2006;176:2391–2395.
  15. Zhang L., Li XS., Zhou LQ. (2016) Renal Tumor Biopsy Technique. Chinese Medical Journal; 2016;20:1236–1240.
  16. Kay F.U., Pedrosa I. Imaging of Solid Renal Masses. Radiologic Clinics of North America. 2017;55(2):243–258.
  17. Reznek R.H. CT/MRI in staging renal cell carcinoma. Cancer Imaging 2004; 4(spec no A):S25–S32.
  18. Cornelis F., Tricaud E. et al. Routinely performed multiparametric magnetic resonance imaging helps to differentiate common subtypes of renal tumours. European Society of Radiology. 2014.
  19. Kang S.K., Zhang A., Pandharipande P.V., et al. DWI for renal mass characterization: systematic review and meta-analysis of diagnostic test performance. AJR Am J Roentgenol. 2015;205(2):317–324.
  20. Gündoğana C., Çermika TF., et al. Role of contrast-enhanced 18F-FDG PET/CT imaging in the diagnosis and staging of renal tumors. Nuclear Medicine Communications. 2018;39:1174–1182.
  21. Zhang L., Li X.S., Zhou L.Q. Renal Tumor Biopsy Technique. Chin Med J. 2016;129:1236–1240.
  22. Roussel E., Capitanio U. et al. Novel Imaging Methods for Renal Mass Characterization: A Collaborative Review European urology. 2022;81:476–488.
  23. Marconi L, Dabestani S, Lam TB, et al. Systematic review and meta-analysis of diagnostic accuracy of percutaneous renal tumour biopsy. Eur Urol. 2016;69(4):660–673.
  24. Princea J., Bultman E. et al. Patient and tumor characteristics can predict nondiagnostic renal mass biopsy findings. J Urol. 2015;193(6):1899–1904.
  25. Haider Rahbar, Sam Bhayani et al. Evaluation of Renal Mass Biopsy Risk Stratification Algorithm for Robotic Partial Nephrectomy – Could a Biopsy Have Guided Management? The journal of urology. 2014;192:1337–1342.
  26. Ognerubov N.A., Shatov I.A., Shatov A.V. Radiogenomics and radiomics in the diagnosis of malignant tumors: literature review. Bulletin of the Tambov University. Natural and Technical Sciences series. Tambov, 2017;22(6):1453-1460. Russian (Огнерубов Н.А., Шатов И.А., Шатов А.В. Радиогеномика и радиомика в диагностике злокачественных опухолей: обзор литературы. Вестник Тамбовского университета. Серия Естественные и технические науки. Тамбов, 2017; 22(6):1453–1460).
  27. Davnall F., Yip C.S., Ljungqvist G., Selmi M., Ng F., Sanghera B. et al. Assessment of tumor heterogeneity: an emerging imaging tool for clinical practice? Insights Imaging. 2012;3 (6):573–589.
  28. Varghese B.A., Chen F., Hwang D.H., Cen S.Y., Desai B., Gill I.S. и др. Differentiation of Predominantly Solid Enhancing Lipid-Poor Renal Cell Masses by Use of Contrast Enhanced CT: Evaluating the Role of Texture in Tumor Subtyping. AJR Am J Roentgenol. 2018;211(6):W288-W296.
  29. Nie P., Yang G., Wang Z., Yan L., Miao W., Hao D. и др. A CT-based radiomics nomogram for differentiation of renal angiomyolipoma without visible fat from homogeneous clear cell renal cell carcinoma. EurRadiol. 2020;30(2):1274–1284.
  30. Bektas C.T., Kocak B., Yardimci A.H., Turkcanoglu M.H., Yucetas U., Koca S.B., et al. Clear Cell Renal Cell Carcinoma: Machine Learning-Based Quantitative Computed Tomography Texture Analysis for Prediction of Fuhrman Nuclear Grade. Euro Radiol 2019; 29(3):1153–1163. https://doi.org/10.1007/s00330-018-5698-2
  31. Luo S., Wei R., Lu S., Lai S., Wu J., Wu Z., Pang X., Wei X., Jiang X., Zhen X., Yang R. Fuhrman nuclear grade prediction of clear cell renal cell carcinoma: influence of volume of interest delineation strategies on machine learning-based dynamic enhanced CT radiomics analysis. European Radiology. 2022;32:2340–2350.
  32. Kierans A.S., Rusinek H., Lee A., et al. Textural Differences in apparent diffusion coeffificient between low- and high-stage clear cell renal cell carcinoma. Am J Roentgenol. 2014; 203:W637–W644. doi: 10.2214/AJR.14.12570.
  33. Alyaev Yu.G., Sirota E.S., Proskura A.V. Digitalization of operations for kidney tumors. M.: GEOTAR-Media, 2021. p. 10-35. Russian (Аляев Ю.Г., Сирота Е.С., Проскура А.В. Цифровизация операций при опухоли почки. М.: ГЭОТАР-Медиа, 2021:10–35).
  34. Sirota E.S., Gorduladze D.N., Rapoport L.M., Gridin V.N., Tsarichenko D.G., Kuznetsov I.A., Bochkarev P.V., Alyaev Yu.G. Noninvasive morphological diagnostics of localized formations of the renal parenchyma (pilot study). REJR 2021;11(4):94–104. doi: 10.21569/2222-7415-2021-11-4-94-10. Russian (Сирота Е.С., Гордуладзе Д.Н., Рапопорт Л.М., Гридин В.Н., Цариченко Д.Г., Кузнецов И.А., Бочкарёв П.В., Аляев Ю.Г. Неинвазивная морфологическая диагностика локализованных образований паренхимы почки (пилотное исследование). REJR 2021;11(4):94–104. doi: 10.21569/2222-7415-2021-11- 4-94-104).
  35. Minardi D., Lucarini G., Mazzucchelli R. et al. Prognostic role of Fuhrman grade and vascular endothelial growth factor in pT1a clear cell carcinoma in partial nephrectomy specimens. J Urol. 2005;174:1208–1212.
  36. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383. doi: 10.1016/0021-9681(87)90171-8. PMID: 3558716.
  37. Huang H., Chen S., Li W., Wu X., Xing J. High perirenal fat thickness predicts a poor progression-free survival in patients with localized clear cell renal cell carcinoma. Urol Oncol. 2018;36(4):157.e1-157.e6. doi: 10.1016/j.urolonc.2017.12.011.
  38. Zheng Y., Bao L., Wang W., Wang Q., Pan Y., Gao X. Prognostic impact of the Controlling Nutritional Status score following curative nephrectomy for patients with renal cell carcinoma. Medicine. 2018;97:e13409.
  39. Kang H.W., Kim S.M., Kim W.T., Yun S.J., Lee S.C., Kim W.J., Hwang E.C., Kang S.H., Hong S.H., Chung J., Kwon T.G., Kim H.H., Kwak C., Byun S.S., Kim Y.J. KORCC (KOrean Renal Cell Carcinoma) Group. The age-adjusted Charlson comorbidity index as a predictor of overall survival of surgically treated non-metastatic clear cell renal cell carcinoma. J Cancer Res Clin Oncol. 2020;146(1):187–196. doi: 10.1007/s00432-019-03042-7.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Scheme of the radiomic process

Download (123KB)
Indexing metadata
3. Fig. 2. Finding the minimum volume ellipsoid describing the tumor and their characteristics

Download (59KB)
Indexing metadata

Copyright (c) 2023 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies